SAN FRANCISCO, CA–(Marketwired – December 23, 2015) –
Exosome Sciences, a majority-owned subsidiary of Aethlon Medical Inc. (AEMD), is pioneering the potential use of an exosome-based biomarker to diagnose chronic traumatic encephalopathy (CTE), a condition that otherwise can only be identified postmortem. As James “Jim” Joyce, executive chairman, tells The Life Sciences Report, other companies are exploring this approach in oncology, but Exosome Sciences is the only company advancing an exosome-based candidate to diagnose CTE.
The Life Sciences Report: How did Exosome Sciences, a majority-owned subsidiary of Aethlon Medical Inc., come to be?
James Joyce: Exosome Sciences grew out of our scientific advances at Aethlon Medical, where we have pioneered the development of affinity biofiltration therapies that eliminate life-threatening disease targets from the circulatory system. We formed Exosome Sciences to evolve exosome isolation techniques that we developed at Aethlon Medical for therapeutic purposes into a diagnostic setting. Exosomes are very stable nanometer-size vesicles that transport disease-specific cargos throughout the body.
In the case of neurological disorders, we pursued a belief that it might be able to isolate disease-specific exosomes that crossed through the blood-brain barrier and into the blood, thus establishing the possibility of liquid biopsy that could detect and monitor…
About Streetwise Reports – The Life Sciences Report